investing in high yielding corporate and
Name | % Net Assets |
---|---|
Boots 5.5% £ Bonds 26/5/2009 | 1.8% |
VNU 5.625% £ MTN 20/5/2010 | 1.3% |
Rhodia € FRN 15/10/2013 | 1.3% |
Linde 8.125% £ Bonds 14/7/2016 | 1.3% |
GlaxoSmithKline | 1.3% |
AstraZeneca | 1.3% |
NTL Cable 9.75% £ Bonds 15/4/2014 | 1.2% |
SLM 5.375% £ Bonds 15/12/2010 | 1.2% |
BG | 1.1% |
BP | 1.1% |
Key | % Net Assets |
---|---|
Boots 5.5% £ Bonds 26/5/2009 | 1.8% |
VNU 5.625% £ MTN 20/5/2010 | 1.3% |
Rhodia € FRN 15/10/2013 | 1.3% |
Linde 8.125% £ Bonds 14/7/2016 | 1.3% |
Other | 94.3% |
Date | 26-May-2017 |
---|---|
NAV | 388.71p |
Currency | GBP |
Change | 0.000p |
% | n/a |
YTD change | 388.71p |
YTD % | n/a |
Fund Inception | 06/02/1999 |
---|---|
Fund Manager | Paul Causer / Paul Read / Neil Woodford |
TER | 1.44 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | £100 |
Savings | £20 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.42% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.00 |
Sharpe ratio | 0.61 |
You are here: research